Gufic Biosciences Limited (GUFICBIO) fundamentals
Gufic Biosciences Limited is a listed company in Pharmaceuticals & Biotechnology, part of the Healthcare sector, listed on the NSE as GUFICBIO (ISIN INE742B01025). This page carries its reported financials, balance sheet, cash flow, shareholding pattern and valuation ratios.
What Gufic Biosciences Limited does
Gufic Biosciences Limited is an India-based company, which is engaged in the manufacturing and marketing of active pharmaceutical ingredients, generic pharmaceuticals and related services. The Company operates in the pharmaceutical segment. It has pharmaceutical products under categories, such as Criti Care, including Doxific, Micafung, Rabol and Tigefic-Plus; Criticare Life, including Ticofic-200 and Gufivan-500; Ferticare, including Puregraf 75IU 3D, Cetrocare 0.25mg 3D and Follicare 150IU 3D; Spark, including Aznee Duo, Eclin, Flabone, Vipro M and Zad G; Herbal, including Bocomo-Forte, Sallaki-Liniment, Zulcer Cap and Smashit tablet, and Aesthaderm, including Prosil, Moiseta Face Wash and Revanox Serum. Its personal care products include StretchNil, Shapers-Natural Feel, Shaper-DryFeel and RollOn. Its products under active pharmaceutical ingredient (API)/bulk drugs include Micafungin, Anidulafungin, Sulconazole and Everolimus. Its Gufic Stridden includes Irvical and Eve.
Valuation and market data
| Last close | ₹426.00 |
|---|---|
| Market capitalisation | ₹4,274 crore |
| Enterprise value | ₹4,371 crore |
| P/E (TTM) | 66.56 |
| Price to book | 6.43 |
| Price to sales (TTM) | 2.55 |
| Book value per share | ₹66.28 |
| Dividend yield | 4.69% |
| Sector | Healthcare |
| Industry | Pharmaceuticals & Biotechnology |
| Listed since | Tue Oct 19 |
Annual results
| Period | Revenue | Profit before tax | Net profit | EPS |
|---|---|---|---|---|
| Mar 2026 | ₹947 crore | ₹87 crore | ₹64 crore | 6.40 |
| Mar 2025 | ₹823 crore | ₹94 crore | ₹70 crore | 6.95 |
| Mar 2024 | ₹809 crore | ₹116 crore | ₹86 crore | 8.74 |
Figures are as reported (consolidated), in ₹ crore.
Shareholding pattern
As of Jun 2026:
| Promoters | 72.5% |
|---|---|
| Foreign institutions (FII) | 0.5% |
| Mutual funds | 3.4% |
| Other domestic institutions | 0.2% |
| Retail and others | 23.4% |
More on BreakPoint
FundaX company research covers every listed company with reported financials. BreakPoint Pro adds the BreakPoint iQ score, the screener and the multibagger board.
Data is sourced from exchange filings and vendor feeds and is for research, not investment advice. Figures can be restated by the company after publication.